**2. The results**

A computer prediction of the antioxidant activity of new compounds was carried out in the "Microcosm" software [4], and the high predictive ability of the "Microcosm" information technology regarding the antioxidant activity of imidazo-benzimidazole derivatives has been demonstrated.

Condensed benzimidazole derivatives were synthesized, and experimental screening of the antioxidant activity of new chemical compounds was carried out among the derivatives of 2-(hetaryl) imidazo[1,2-a]benzimidazoles (IMBI) [5], 3-aroyl- and 3-hetaroyl-IMBI [6], 2-methoxyphenyl-substituted 9-dialkylaminoethyl-IMBI [7], 2-methoxy- phenyl- and 2-oxyphenyl-substituted 1-dialkylaminoalkyl-IMBI [8], N-acylmethyl derivatives of 9H-2,3-dihydro-IMBI and 10H-2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazoles [9], 9-dialkylaminoethyl-2-oxy(dioxy)phenyl-IMBI [10], aroylmethyl derivatives of tricyclic benzimidazole systems containing hydroxy groups in aroyl radicals [11], 3-(2,2,2-trichloro-1-hydroxyethyl)-IMBI [12], 3-acetyl-2-R-9-dialkylaminoethyl-IMBI [13], 1-dialkyl(alkyl)aminoethyl-2,3-dihydro-IMBI [14], 9-R-2-halogenophenyl-IMBI [15], 10-alkylaminoethyl-2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazoles [16], 3-(n,n-disubstituted)acetamide-1-r-2-aminobenzimidazolium [17], amides of 2,3-dihydroimidazo- and 2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazolyl-acetic acids [18], phenyl- and alkylthiocarbamides of 2,9-disubstituted IMBI [19], and 1-substituted 2-benzylaminobenzimidazoles with phenyl methoxyls [20]. Butylated hydroxytoluene (BHT, CAS Number 128-37-0), also known as dibunol, was chosen as a comparative drug.

It was found that among the derivatives of 2-(hetaryl)-IMBI, high antioxidant activity superior to dibunol was shown by compounds containing in the second position of the tricycle such substituents as 1-methylbenzimidazolyl and 5-bromothienyl. The remaining substances of this series showed an average level of activity, similar to or inferior to dibunol [5]. Among the 3-aroyl- and 3-hetaroyl-IMBI, no substances with antioxidant activity were found [6]. Among 2-methoxyphenylsubstituted 9-dialkylaminoethyl-IMBI, 4-methoxy- and 3 methoxyphenyl-IMBI showed the greatest antioxidant effect, which was comparable to or exceeded dibunol [7]. Salts of the compounds 9-dialkylaminoethyl-IMBI with 3,4-dioxyphenyl substitute exhibited the greatest antioxidant activity that was twofold active than reference drug BHT. Compounds with 4- and 3-oxyphenyl substitutes or 2,4- and 2,5-dioxyphenyl substitutes, as a rule, laсked 3,4-dioxyphenyl-IMBI in activity; however they were similar in it to BHT [10]. Most of aroylmethyl derivatives of tricyclic benzimidazole systems containing hydroxy groups in aroyl radicals also proved to be highly active antioxidant substances that were superior to dibunol [11]. Derivatives of 9-R-2-halogenophenyl-IMBI had a pronounced inhibitory effect on the processes of lipid peroxidation comparable to dibunol [15]. The compounds from the series of 1-substituted 2-benzylaminobenzimidazoles with phenyl methoxyls acted similarly [20]. Amides of 2,3-dihydroimidazo- and 2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazolyl-acetic acids showed moderate AO activity compared to dibunol [18]. It was revealed that 2-methoxy-phenyl- and 2-oxyphenyl-substituted 1-dialkylaminoalkyl-IMBI [8], N-acylmethyl derivatives

**247**

*Condensed Benzimidazoles Are a Novel Scaffold for Antioxidant Agents' Search and Development*

As a result of previous investigations, the 2-(3,4-dihydroxyphenyl)-9-diethylaminoethyl-imidazo [1,2-a]benzimidazole derivative of dihydrobromide (RU-185, enoxifol) was identified as an antioxidant compound with antiradical and membrane-protective properties [21, 22], having multicomponent mechanisms of action and a wide range of pharmacodynamic effects. For enoxifol, a cardioprotective effect and a positive effect on the microcirculation of blood vessels are characteristic. Antioxidant compound reduces platelet aggregation [23–25], reduces increased blood viscosity, and increases red blood cell deformability [26]. Preclinical toxicology studies have been carried out, and the pharmacokinetics of the compound has

Synthesis of 2-(3,4-dihydroxyphenyl)-9-diethylamino-ethylimidazo[1,2-a] benzimidazole dihydrobromide (RU-185) starts from saponification of benzimidazole-2-carbamic acid methyl ester under alkaline conditions to obtain 2-aminobenzimidazole. Subsequent alkylation in acetone in the presence of alkali with *N*,*N*-diethylaminoethyl chloride formed by the action of thionyl chloride on *N*,*N*diethylaminoethanol and condensation with a 3,4-dimetoxiphenacylbromide or or 3,4-dioxiphenacyl chloride, followed by intermolecular cyclization in 48% hydrobromic acid (boiling temperature 127°C) under reflux, afforded target compound

2-Aminobenzimidazole is obtained by saponification of benzimidazole-2-carbamic acid methyl ester (BMС-2) in aqueous solution of sodium hydroxide. The yield of 2-aminobenzimidazole is 65–75%. At the next stage, 2-aminobenzimidazole is used with a melting point of 223–232°С (within 2 degrees). If necessary, the amine is purified by crystallization from water and acetone or by precipitation from

*2.1.1 Stage 1: preparation of 2-aminobenzimidazole*

an aqueous hydrochloric acid solution.

of 9H-2,3-dihydro-IMBI and 10H-2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazoles [9], most of 3-(2,2,2-trichloro-1-hydroxyethyl)-IMBI [12] и 3-acetyl-2-R-9-dialkylaminoethyl-IMBI [13], 1-dialkyl(alkyl)aminoethyl-2,3-dihydro-IMBI [14], and 3-(n,n-disubstituted)acetamide-1-r-2-aminobenzimidazolium [17] showed the weak antioxidant activity compared to the reference drug. Among 10-alkylaminoethyl-2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazoles [16] and phenyl- and alkylthiocarbamides of 2,9-disubstituted IMBI [19], antioxidant action has not been

*DOI: http://dx.doi.org/10.5772/intechopen.82817*

found.

been studied [27].

**2.1 Synthesis**

RU-185.

*Condensed Benzimidazoles Are a Novel Scaffold for Antioxidant Agents' Search and Development DOI: http://dx.doi.org/10.5772/intechopen.82817*

of 9H-2,3-dihydro-IMBI and 10H-2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazoles [9], most of 3-(2,2,2-trichloro-1-hydroxyethyl)-IMBI [12] и 3-acetyl-2-R-9-dialkylaminoethyl-IMBI [13], 1-dialkyl(alkyl)aminoethyl-2,3-dihydro-IMBI [14], and 3-(n,n-disubstituted)acetamide-1-r-2-aminobenzimidazolium [17] showed the weak antioxidant activity compared to the reference drug. Among 10-alkylaminoethyl-2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazoles [16] and phenyl- and alkylthiocarbamides of 2,9-disubstituted IMBI [19], antioxidant action has not been found.

As a result of previous investigations, the 2-(3,4-dihydroxyphenyl)-9-diethylaminoethyl-imidazo [1,2-a]benzimidazole derivative of dihydrobromide (RU-185, enoxifol) was identified as an antioxidant compound with antiradical and membrane-protective properties [21, 22], having multicomponent mechanisms of action and a wide range of pharmacodynamic effects. For enoxifol, a cardioprotective effect and a positive effect on the microcirculation of blood vessels are characteristic. Antioxidant compound reduces platelet aggregation [23–25], reduces increased blood viscosity, and increases red blood cell deformability [26]. Preclinical toxicology studies have been carried out, and the pharmacokinetics of the compound has been studied [27].

#### **2.1 Synthesis**

*Antioxidants*

**2. The results**

as a comparative drug.

arouse the interest of qualified specialists.

synthetic compounds are used [3]. It should be noted that the group of drugs related to natural antioxidants has found quite wide application in clinical practice. At the same time, there is a clear shortage of synthetic antioxidant drugs. In view of the abovementioned, the emergence of a new effective antioxidant compound should

A computer prediction of the antioxidant activity of new compounds was carried out in the "Microcosm" software [4], and the high predictive ability of the "Microcosm" information technology regarding the antioxidant activity of

Condensed benzimidazole derivatives were synthesized, and experimental screening of the antioxidant activity of new chemical compounds was carried out among the derivatives of 2-(hetaryl) imidazo[1,2-a]benzimidazoles (IMBI) [5], 3-aroyl- and 3-hetaroyl-IMBI [6], 2-methoxyphenyl-substituted 9-dialkylaminoethyl-IMBI [7], 2-methoxy- phenyl- and 2-oxyphenyl-substituted 1-dialkylaminoalkyl-IMBI [8], N-acylmethyl derivatives of 9H-2,3-dihydro-IMBI and 10H-2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazoles [9], 9-dialkylaminoethyl-2-oxy(dioxy)phenyl-IMBI [10], aroylmethyl derivatives of tricyclic

benzimidazole systems containing hydroxy groups in aroyl radicals [11], 3-(2,2,2-trichloro-1-hydroxyethyl)-IMBI [12], 3-acetyl-2-R-9-dialkylaminoethyl-IMBI [13], 1-dialkyl(alkyl)aminoethyl-2,3-dihydro-IMBI [14], 9-R-2-halogenophenyl-IMBI [15], 10-alkylaminoethyl-2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazoles [16], 3-(n,n-disubstituted)acetamide-1-r-2-aminobenzimidazolium [17], amides of 2,3-dihydroimidazo- and 2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazolyl-acetic acids [18], phenyl- and alkylthiocarbamides of 2,9-disubstituted IMBI [19], and 1-substituted 2-benzylaminobenzimidazoles with phenyl methoxyls [20]. Butylated hydroxytoluene (BHT, CAS Number 128-37-0), also known as dibunol, was chosen

It was found that among the derivatives of 2-(hetaryl)-IMBI, high antioxidant activity superior to dibunol was shown by compounds containing in the second position of the tricycle such substituents as 1-methylbenzimidazolyl and 5-bromothienyl. The remaining substances of this series showed an average level of activity, similar to or inferior to dibunol [5]. Among the 3-aroyl- and 3-hetaroyl-IMBI, no substances with antioxidant activity were found [6]. Among 2-methoxyphenylsubstituted 9-dialkylaminoethyl-IMBI, 4-methoxy- and 3 methoxyphenyl-IMBI showed the greatest antioxidant effect, which was comparable to or exceeded dibunol [7]. Salts of the compounds 9-dialkylaminoethyl-IMBI with 3,4-dioxyphenyl substitute exhibited the greatest antioxidant activity that was twofold active than reference drug BHT. Compounds with 4- and 3-oxyphenyl substitutes or 2,4- and 2,5-dioxyphenyl substitutes, as a rule, laсked 3,4-dioxyphenyl-IMBI in activity; however they were similar in it to BHT [10]. Most of aroylmethyl derivatives of tricyclic benzimidazole systems containing hydroxy groups in aroyl radicals also proved to be highly active antioxidant substances that were superior to dibunol [11]. Derivatives of 9-R-2-halogenophenyl-IMBI had a pronounced inhibitory effect on the processes of lipid peroxidation comparable to dibunol [15]. The compounds from the series of 1-substituted 2-benzylaminobenzimidazoles with phenyl methoxyls acted similarly [20]. Amides of 2,3-dihydroimidazo- and 2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazolyl-acetic acids showed moderate AO activity compared to dibunol [18]. It was revealed that 2-methoxy-phenyl- and 2-oxyphenyl-substituted 1-dialkylaminoalkyl-IMBI [8], N-acylmethyl derivatives

imidazo-benzimidazole derivatives has been demonstrated.

**246**

Synthesis of 2-(3,4-dihydroxyphenyl)-9-diethylamino-ethylimidazo[1,2-a] benzimidazole dihydrobromide (RU-185) starts from saponification of benzimidazole-2-carbamic acid methyl ester under alkaline conditions to obtain 2-aminobenzimidazole. Subsequent alkylation in acetone in the presence of alkali with *N*,*N*-diethylaminoethyl chloride formed by the action of thionyl chloride on *N*,*N*diethylaminoethanol and condensation with a 3,4-dimetoxiphenacylbromide or or 3,4-dioxiphenacyl chloride, followed by intermolecular cyclization in 48% hydrobromic acid (boiling temperature 127°C) under reflux, afforded target compound RU-185.

#### *2.1.1 Stage 1: preparation of 2-aminobenzimidazole*

2-Aminobenzimidazole is obtained by saponification of benzimidazole-2-carbamic acid methyl ester (BMС-2) in aqueous solution of sodium hydroxide. The yield of 2-aminobenzimidazole is 65–75%. At the next stage, 2-aminobenzimidazole is used with a melting point of 223–232°С (within 2 degrees). If necessary, the amine is purified by crystallization from water and acetone or by precipitation from an aqueous hydrochloric acid solution.

*2.1.2 Stage 2: preparation of diethylaminoethyl chloride hydrochloride*

$$\begin{array}{ccccc} \text{\huge{1cm}} & \text{\huge{1cm}} & \text{\huge{1cm}} & \text{\huge{1cm}} & \text{\huge{1cm}} & \text{\huge{1cm}} & \text{\huge{1cm}} \\ \text{\huge{1cm}} & \text{\huge{1cm}} & \text{\huge{1cm}} & \text{\huge{1cm}} & \text{\huge{1cm}} & \text{\huge{1cm}} \\ \text{\huge{1cm}} & \text{\huge{1cm}} & \text{\huge{1cm}} & \text{\huge{1cm}} & \text{\huge{1cm}} & \text{\huge{1cm}} \\ \end{array}$$

Diethylaminoethyl chloride hydrochloride is obtained by chlorination of diethylaminoethanol with thionyl chloride in toluene or benzene. Purification can be performed by distillation at atmospheric pressure, collecting the fraction with 161–162°C boiling point.

Diethylaminoethanol was distilled in case of poor quality and dried over anhydrous potassium carbonate (1:10 w/v) prior to use. After standing for 6–8 hours with periodic stirring, the desiccant was filtered off. Thionyl chloride (technical) was also distilled at atmospheric pressure before use (boiling point 74–75°C).

#### *2.1.3 Stage 3: synthesis of 2-amino-1-diethylaminoethylbenzimidazole*

2-Amino-1-diethylaminoethylbenzimidazole is obtained by alkylation of 2-aminobenzimidazole with N,N-diethylaminoethyl chloride in acetone in a presence of a concentrated alkali solution. Upon completion of the reaction, the acetone is distilled off at atmospheric pressure and can be used at the same stage without further purification. Water is added to the residue, and the precipitate of the alkylated amine is filtered off to give 82–88% yield.

#### *2.1.4 Stage 4: 2-(3,4-dihydroxyphenyl)-9-diethylaminoethyl-imidazo[1,2-a]benzimidazole dihydrobromide (RU-185)*

Synthesis of compound RU-185 is achieved by treatment of 2-amino-1-diethylaminoethylbenzimidazole with α-chloro-3,4-dihydroxyacetophenone [28] (Method A) or with 3,4-dimethoxyphenacyl bromide. Subsequent cyclization of the formed quaternary 2-aminobenzimidazole salts is achieved in concentrated HBr (Method B).

**249**

**Figure 1.**

*Condensed Benzimidazoles Are a Novel Scaffold for Antioxidant Agents' Search and Development*

**Method A** The method consists of boiling of 1-diethylaminoethyl-2-aminobenzimidazole and α-chloroacetopyrocatechol in dry acetonitrile until the quaternization reaction is complete (2–3 hours with TLC control). Then the solvent is evaporated to dryness, and concentrated HBr is added followed by reflux for 1–2 hours. Reaction mixture is left overnight in the refrigerator. The next day, the precipitate formed (large needles) is filtered off. The yield of dihydrobromide (I) is 97%. Recrystallization of the crude product from 80% aqueous ethanol with addition of activated charcoal affords white crystals with a yield of 85%. The product should be protected from direct sunlight. After drying at 110–120°C, the melting

**Method B** 3,4-Dimethoxyphenacyl bromide is added to a hot solution of 2-amino-1-diethylaminoethylbenzimidazole in acetone (molar ratio 1:1). Next, the mixture is kept for 6–8 hours at room temperature. The precipitate of 2-amino-(3,4 dimethoxyphenacyl)-1-diethylaminoethylbenzimidazolium bromide is filtered off. The output is 93.5% and melting point 182°C (decomposition, from ethanol).

Next, the resulting bromide is refluxed in conc. HBr (127°C) for 6–8 hours, while as the boiling of the initially formed solution precipitates. After cooling, it is filtered off, washed with acetone, and air dried. The yield is 96%. Crystallization from 80% aqueous ethanol gives (3,4-dihydroxyphenyl)-9-diethylaminoethyl-imidazo[1,2-a] benzimidazole dihydrobromide (I) identical to the product described in method A.

For several years, the ability of compounds to inhibit oxidative processes in the cells of various tissues, organs, and biological fluids has been thoroughly investigated. The study of the antioxidant properties of enoxifol was carried out by several methods: ascorbate-induced LPO according to the method [29], Fe2+ induced chemiluminescence (CL) of lipids [30], and NADPH-dependent LPO [31]. Superoxide dismutase-like activity has been studied in a quercetin oxidation model [32], interaction with the free radical of 2,2-diphenyl-1-picrylhydrazyl (DPPH\*) according to the method [33], and interaction with reactive oxygen species on the luminol-dependent CL model [34], the ability to inactivate the superoxide anion radical was estimated by the xanthine-xanthine oxidase-induced lucigenindependent CL method [2], and the ability of substances to intercept and inactivate the peroxyl radical was determined by the ABAP-induced CL method [35]. The spectrum of antioxidant activity of enoxifol and the reference compound trolox is shown on **Figure 1**. It was found that enoxifol can react with lipid peroxyl radicals

*DOI: http://dx.doi.org/10.5772/intechopen.82817*

**2.2 Pharmacological properties**

*2.2.1 Antioxidant activity*

point of dihydrobromide is 289–290°C (decomposition).

*Antioxidant activity spectrum of enoxifol (A) and trolox (B) (−Lg IC50 (М)).*

*Condensed Benzimidazoles Are a Novel Scaffold for Antioxidant Agents' Search and Development DOI: http://dx.doi.org/10.5772/intechopen.82817*

**Method A** The method consists of boiling of 1-diethylaminoethyl-2-aminobenzimidazole and α-chloroacetopyrocatechol in dry acetonitrile until the quaternization reaction is complete (2–3 hours with TLC control). Then the solvent is evaporated to dryness, and concentrated HBr is added followed by reflux for 1–2 hours. Reaction mixture is left overnight in the refrigerator. The next day, the precipitate formed (large needles) is filtered off. The yield of dihydrobromide (I) is 97%. Recrystallization of the crude product from 80% aqueous ethanol with addition of activated charcoal affords white crystals with a yield of 85%. The product should be protected from direct sunlight. After drying at 110–120°C, the melting point of dihydrobromide is 289–290°C (decomposition).

**Method B** 3,4-Dimethoxyphenacyl bromide is added to a hot solution of 2-amino-1-diethylaminoethylbenzimidazole in acetone (molar ratio 1:1). Next, the mixture is kept for 6–8 hours at room temperature. The precipitate of 2-amino-(3,4 dimethoxyphenacyl)-1-diethylaminoethylbenzimidazolium bromide is filtered off. The output is 93.5% and melting point 182°C (decomposition, from ethanol).

Next, the resulting bromide is refluxed in conc. HBr (127°C) for 6–8 hours, while as the boiling of the initially formed solution precipitates. After cooling, it is filtered off, washed with acetone, and air dried. The yield is 96%. Crystallization from 80% aqueous ethanol gives (3,4-dihydroxyphenyl)-9-diethylaminoethyl-imidazo[1,2-a] benzimidazole dihydrobromide (I) identical to the product described in method A.

#### **2.2 Pharmacological properties**

#### *2.2.1 Antioxidant activity*

*Antioxidants*

161–162°C boiling point.

*2.1.2 Stage 2: preparation of diethylaminoethyl chloride hydrochloride*

*2.1.3 Stage 3: synthesis of 2-amino-1-diethylaminoethylbenzimidazole*

ated amine is filtered off to give 82–88% yield.

*dihydrobromide (RU-185)*

Diethylaminoethyl chloride hydrochloride is obtained by chlorination of diethylaminoethanol with thionyl chloride in toluene or benzene. Purification can be performed by distillation at atmospheric pressure, collecting the fraction with

2-Amino-1-diethylaminoethylbenzimidazole is obtained by alkylation of 2-aminobenzimidazole with N,N-diethylaminoethyl chloride in acetone in a presence of a concentrated alkali solution. Upon completion of the reaction, the acetone is distilled off at atmospheric pressure and can be used at the same stage without further purification. Water is added to the residue, and the precipitate of the alkyl-

*2.1.4 Stage 4: 2-(3,4-dihydroxyphenyl)-9-diethylaminoethyl-imidazo[1,2-a]benzimidazole* 

Synthesis of compound RU-185 is achieved by treatment of 2-amino-1-diethylaminoethylbenzimidazole with α-chloro-3,4-dihydroxyacetophenone [28] (Method A) or with 3,4-dimethoxyphenacyl bromide. Subsequent cyclization of the formed quaternary 2-aminobenzimidazole salts is achieved in concentrated HBr (Method B).

Diethylaminoethanol was distilled in case of poor quality and dried over anhydrous potassium carbonate (1:10 w/v) prior to use. After standing for 6–8 hours with periodic stirring, the desiccant was filtered off. Thionyl chloride (technical) was also distilled at atmospheric pressure before use (boiling point 74–75°C).

**248**

For several years, the ability of compounds to inhibit oxidative processes in the cells of various tissues, organs, and biological fluids has been thoroughly investigated. The study of the antioxidant properties of enoxifol was carried out by several methods: ascorbate-induced LPO according to the method [29], Fe2+ induced chemiluminescence (CL) of lipids [30], and NADPH-dependent LPO [31]. Superoxide dismutase-like activity has been studied in a quercetin oxidation model [32], interaction with the free radical of 2,2-diphenyl-1-picrylhydrazyl (DPPH\*) according to the method [33], and interaction with reactive oxygen species on the luminol-dependent CL model [34], the ability to inactivate the superoxide anion radical was estimated by the xanthine-xanthine oxidase-induced lucigenindependent CL method [2], and the ability of substances to intercept and inactivate the peroxyl radical was determined by the ABAP-induced CL method [35]. The spectrum of antioxidant activity of enoxifol and the reference compound trolox is shown on **Figure 1**. It was found that enoxifol can react with lipid peroxyl radicals

**Figure 1.** *Antioxidant activity spectrum of enoxifol (A) and trolox (B) (−Lg IC50 (М)).*

at the chain termination stage, as indirectly evidenced by its high inhibitory activity during ascorbate, NADPH-induced lipid peroxidation, and CL of lipids, as well as directly inactivate superoxide, hydroxyl, and peroxyl radicals that initiate oxidation, as demonstrated in reactions with the free radical DPPH, quercetin oxidation, Fe2+-induced CL in the presence of luminol, xanthine-xanthine oxidase induced by lucigenin-dependent CL, as well as thermal decomposition of the water-soluble compound 2,2-azobis (2-methylpropionamidine) dihydrochloride (ABAP) with the release of peroxyl radicals, inactivating free radicals and enoxifol, thereby reducing the overall oxidation rate by reducing the total initiation rate [35, 36].

As a result of the analysis of the chemical structure of enoxifol, the structural descriptors were determined, allowing the compound to exhibit antioxidant and antiradical activities. The molecule of enoxifol can manifest these properties due to a fragment of 3,4-dihydroxyphenyl and π-electronic redundancy of the imidazole ring in the structure of imidazobenzimidazoles [37]. Given the relatively low toxicity and high antioxidant potential, the compound was selected for in-depth study on pathological models.

### *2.2.2 Membranoprotective properties*

*Membranoprotective activity of enoxifol was studied using the model* [38], determining the mechanical strength and resistance of erythrocyte membranes to the hypoosmotic HCl solution. The membrane-stabilizing activity of the compound (inhibition of slow and fast incoming transmembrane ion currents) has been revealed. An effective dose of a compound of 20.5 mg/kg has been established [39].

#### *2.2.3 Hepatoprotective effects*

When studying the hepatoprotective properties of enoxifol with a 3-day prophylactic administration in dose 2.25 mg/kg on a model of acute tetrachloromethane hepatitis, it was found that enoxifol significantly improved the absorption and excretory function of the liver and its detoxification abilities Under its influence the development of signs of the cytolytic, hepatodepressive, mesenchymal-inflammatory, and cholestatic syndrome was significantly inhibited, surpassing tocopherol acetate in effectiveness [40].

#### *2.2.4 Antihypoxic action*

The antihypoxic properties of enoxifol have been studied in several models of hypobaric, hemic, and tissue hypoxia. In particular, the activity of the compound was established during intrauterine hypoxia and during recovery after acute hypobaric hypoxia. The potential protective effect of the antioxidant compound in hypobaric hypoxia was determined in high- and low-resistant to hypoxia animals in a flow-type pressure chamber at the "height" of 12,500 and 11,000 m, respectively [41]. The most effective doses in these models were 3 and 5 mg/kg [42]. Enoxifol showed a protective effect in modeling intrauterine hypoxia in dose 10 mg/kg during course administration [42].

The activity of the compound in the recovery period after acute hypobaric hypoxia was determined by the change in behavioral reactions, cognitive functions, and the physical condition of the animals. The protective dose of enoxifol was 5 mg/kg. Tissue and hemic hypoxias were created by injecting potassium cyanide and sodium nitrite, respectively [43]. The protective action of enoxifol was judged by the degree of survival of the animals. The range of effective doses was determined from 0.5 to 5 mg/kg [44].

**251**

*Condensed Benzimidazoles Are a Novel Scaffold for Antioxidant Agents' Search and Development*

The cerebroprotective effect of enoxifol was established on two models of cerebral ischemia of two and four vascular ligature of the carotid and paravertebral arteries, respectively, as well as during the reperfusion period [25, 44]. Antioxidant compound significantly increased the survival rate of animals, decreased blood viscosity by reducing platelet and red blood cell (RBC) aggregation and improving the mechanical properties of RBC, and corrected the behavioral deficit in the postischemic period. Doses of enoxifol in which the cerebroprotective activity was

Nootropic activity of enoxifol was established in the model of the conditioned passive avoidance reaction, which allows to evaluate the effect of a studied compounds on learning and memory. As a result, it was found that enoxifol influenced the ability of animals to consolidate information, reduced the deficit in the reproduction of a memorable trace, and intensified the input and initial processing of information in dose 10 mg/kg. The study of the enoxifol effect on the research behavior and emotionality of animals was carried out in the open-field modified test that allows to evaluate the nonassociative behavior of animals in familiar surroundings. Against the background of a 3-day course of administration of the antioxidant compound in dose of 10 mg/kg, psycho-emotional reactivity and anxiety in animals were decreased. With repeated testing, the memories of the arena research were better preserved. Experiments conducted in a Morris maze test confirmed the potential ability of enoxifol in a similar dose to increase mnestic abilities and

The stress-protective effect of enoxifol was studied on models of short-term (1 hour) and prolonged (48 hours) hypokinetic stress [46] and hyperkinetic stress with the paradoxical sleep phase deprivation in rats, in the test of slowly rotating rod [47]. Enoxifol was administered to animals in doses 5 and 10 mg/kg. An antioxidant compound showed an ambiguous therapeutic effect depending on the experimental model used. The antioxidant was not effective in the short-term hypokinetic stress technique. Enoxifol reduced post-stress injuries of internal organs and corrected the targeted behavior of animals in prolonged hypokinetic stress. Enoxifol did not affect the behavioral activity of rats but protected internal organs

The effect of enoxifol on physical performance and recovery period after physical exertion was studied under normal and complicated conditions in several experimental models. We used the swim to the limit test [48], fatigue development test [49], and efficiency test in anti-orthostatic condition [50]; the model allows to study the recovery process after exercises [51] and the method of research of animals' endurance to training and exhausting loads [49]. Actoprotective properties were studied in models associated with limiting physical loads (swimming to failure), with the rate of fatigue development, and in the test of swimming in complicated anti-orthostatic condition. Enoxifol increased the duration of physical performance under normal and complicated conditions, stabilized some indicators

*DOI: http://dx.doi.org/10.5772/intechopen.82817*

*2.2.5 Cerebroprotective properties*

established were 5 and 10 mg/kg.

improve the spatial orientation of animals [45].

from pathological abnormalities in hyperkinetic stress [37].

*2.2.7 Stress-protective effects*

*2.2.8 Actoprotective activity*

*2.2.6 Nootropic activity*

*Condensed Benzimidazoles Are a Novel Scaffold for Antioxidant Agents' Search and Development DOI: http://dx.doi.org/10.5772/intechopen.82817*

#### *2.2.5 Cerebroprotective properties*

*Antioxidants*

on pathological models.

*2.2.3 Hepatoprotective effects*

acetate in effectiveness [40].

ing course administration [42].

*2.2.4 Antihypoxic action*

*2.2.2 Membranoprotective properties*

at the chain termination stage, as indirectly evidenced by its high inhibitory activity during ascorbate, NADPH-induced lipid peroxidation, and CL of lipids, as well as directly inactivate superoxide, hydroxyl, and peroxyl radicals that initiate oxidation, as demonstrated in reactions with the free radical DPPH, quercetin oxidation, Fe2+-induced CL in the presence of luminol, xanthine-xanthine oxidase induced by lucigenin-dependent CL, as well as thermal decomposition of the water-soluble compound 2,2-azobis (2-methylpropionamidine) dihydrochloride (ABAP) with the release of peroxyl radicals, inactivating free radicals and enoxifol, thereby reducing

As a result of the analysis of the chemical structure of enoxifol, the structural descriptors were determined, allowing the compound to exhibit antioxidant and antiradical activities. The molecule of enoxifol can manifest these properties due to a fragment of 3,4-dihydroxyphenyl and π-electronic redundancy of the imidazole ring in the structure of imidazobenzimidazoles [37]. Given the relatively low toxicity and high antioxidant potential, the compound was selected for in-depth study

*Membranoprotective activity of enoxifol was studied using the model* [38], determining the mechanical strength and resistance of erythrocyte membranes to the hypoosmotic HCl solution. The membrane-stabilizing activity of the compound (inhibition of slow and fast incoming transmembrane ion currents) has been revealed. An effective dose of a compound of 20.5 mg/kg has been established [39].

When studying the hepatoprotective properties of enoxifol with a 3-day prophylactic administration in dose 2.25 mg/kg on a model of acute tetrachloromethane hepatitis, it was found that enoxifol significantly improved the absorption and excretory function of the liver and its detoxification abilities Under its influence the development of signs of the cytolytic, hepatodepressive, mesenchymal-inflammatory, and cholestatic syndrome was significantly inhibited, surpassing tocopherol

The antihypoxic properties of enoxifol have been studied in several models of hypobaric, hemic, and tissue hypoxia. In particular, the activity of the compound was established during intrauterine hypoxia and during recovery after acute hypobaric hypoxia. The potential protective effect of the antioxidant compound in hypobaric hypoxia was determined in high- and low-resistant to hypoxia animals in a flow-type pressure chamber at the "height" of 12,500 and 11,000 m, respectively [41]. The most effective doses in these models were 3 and 5 mg/kg [42]. Enoxifol showed a protective effect in modeling intrauterine hypoxia in dose 10 mg/kg dur-

The activity of the compound in the recovery period after acute hypobaric hypoxia was determined by the change in behavioral reactions, cognitive functions, and the physical condition of the animals. The protective dose of enoxifol was 5 mg/kg. Tissue and hemic hypoxias were created by injecting potassium cyanide and sodium nitrite, respectively [43]. The protective action of enoxifol was judged by the degree of survival of the animals. The range of effective doses was determined from 0.5 to

the overall oxidation rate by reducing the total initiation rate [35, 36].

**250**

5 mg/kg [44].

The cerebroprotective effect of enoxifol was established on two models of cerebral ischemia of two and four vascular ligature of the carotid and paravertebral arteries, respectively, as well as during the reperfusion period [25, 44]. Antioxidant compound significantly increased the survival rate of animals, decreased blood viscosity by reducing platelet and red blood cell (RBC) aggregation and improving the mechanical properties of RBC, and corrected the behavioral deficit in the postischemic period. Doses of enoxifol in which the cerebroprotective activity was established were 5 and 10 mg/kg.

### *2.2.6 Nootropic activity*

Nootropic activity of enoxifol was established in the model of the conditioned passive avoidance reaction, which allows to evaluate the effect of a studied compounds on learning and memory. As a result, it was found that enoxifol influenced the ability of animals to consolidate information, reduced the deficit in the reproduction of a memorable trace, and intensified the input and initial processing of information in dose 10 mg/kg. The study of the enoxifol effect on the research behavior and emotionality of animals was carried out in the open-field modified test that allows to evaluate the nonassociative behavior of animals in familiar surroundings. Against the background of a 3-day course of administration of the antioxidant compound in dose of 10 mg/kg, psycho-emotional reactivity and anxiety in animals were decreased. With repeated testing, the memories of the arena research were better preserved. Experiments conducted in a Morris maze test confirmed the potential ability of enoxifol in a similar dose to increase mnestic abilities and improve the spatial orientation of animals [45].

### *2.2.7 Stress-protective effects*

The stress-protective effect of enoxifol was studied on models of short-term (1 hour) and prolonged (48 hours) hypokinetic stress [46] and hyperkinetic stress with the paradoxical sleep phase deprivation in rats, in the test of slowly rotating rod [47]. Enoxifol was administered to animals in doses 5 and 10 mg/kg. An antioxidant compound showed an ambiguous therapeutic effect depending on the experimental model used. The antioxidant was not effective in the short-term hypokinetic stress technique. Enoxifol reduced post-stress injuries of internal organs and corrected the targeted behavior of animals in prolonged hypokinetic stress. Enoxifol did not affect the behavioral activity of rats but protected internal organs from pathological abnormalities in hyperkinetic stress [37].

#### *2.2.8 Actoprotective activity*

The effect of enoxifol on physical performance and recovery period after physical exertion was studied under normal and complicated conditions in several experimental models. We used the swim to the limit test [48], fatigue development test [49], and efficiency test in anti-orthostatic condition [50]; the model allows to study the recovery process after exercises [51] and the method of research of animals' endurance to training and exhausting loads [49]. Actoprotective properties were studied in models associated with limiting physical loads (swimming to failure), with the rate of fatigue development, and in the test of swimming in complicated anti-orthostatic condition. Enoxifol increased the duration of physical performance under normal and complicated conditions, stabilized some indicators

of energy metabolism (the level of lactate, glycogen, tryptophan, the ratio of pyruvate and lactate), normalized indicators of lipid peroxidation, and had a protective effect on the myocardium of animals during the period of exhaustive physical activity. A number of effective doses amounted to 1, 3, 5, 10, 20, 25, and 50 mg/kg in various physical activity tests [52].
